US40131M1099
© BusinessWire
11.12.2025
GH
LISTED
NASDAQ
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.
News Preview
Guardant Health (Nasdaq: GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care option, today announced a strategic collaboration to increase access to cancer clinical trials in the United States.
The collaboration combines Guardant Health’s suite of cutting-edge precisio...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
GH
LISTED
NASDAQ
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guar...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
GH
LISTED
NASDAQ
Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025.
Oral presentations will highlight...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
12.11.2025
GH
LISTED
NASDAQ
Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 34-member, cross-industry consortium which has drafted the first open standard for exabyte-scale data interoperability. Managing exabyte-scale data across different storage providers is often di...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
10.11.2025
GH
LISTED
NASDAQ
Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its Guardant Reveal® blood test to include late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal tracks more than 20,000 epigenomic (methylation) signals to measure changes in circulating tumor DNA (ctDNA) lev...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
GH
LISTED
NASDAQ
Guardant Health to Participate in Upcoming Investor Conferences
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
Jefferies Global Healthcare Conference in London, UK
Fireside chat on Wednesday, November 19 at 9:30 a.m. Greenwich Mean Time
Piper Sandler 37th Annual Healthcare Conference in New...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
GH
LISTED
NASDAQ
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 21, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 184,961 shares of its common stock to 272 new non-executive employees and one non-qualified stock optio...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
GH
LISTED
NASDAQ
New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating that its Guardant Reveal® blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months earlier than conventional methods. This is the first robust clinical validation study of pan...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
GH
LISTED
NASDAQ
Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening for colorectal cancer (CRC). Shield is the first and only blood test to receive FDA app...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
GH
LISTED
NASDAQ
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
News Preview
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 3,333,333 shares of Guardant Health’s common stock at a public offering price of $90.00 per share (the “common stock offering”). The size of the common stock offering was increased...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
GH
LISTED
NASDAQ
Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering
News Preview
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount of 0% convertible senior notes due 2033 (the “notes”) in a private offering (the “convertible notes offering”) to persons reasonably believed to be qualified...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
GH
LISTED
NASDAQ
Guardant Health Announces Proposed Public Offering of Common Stock
News Preview
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of $250.0 million of shares of Guardant Health’s common stock (the “common stock offering”). Guardant Health also intends to grant the underwriters a 30-day option to purchase up to an ad...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
04.11.2025
GH
LISTED
NASDAQ
Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033
News Preview
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2033 (the “notes”) in a private offering (the “convertible notes offering”) to persons reasonably believed to be qualified institutional buyer...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
GH
LISTED
NASDAQ
Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025.
Third Quarter 2025 Financial Highlights
For the three-month period ended September 30, 2025, as compared to the same period of 2024:
Reported total revenue of $265.2 million, an increase of 39%...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
GH
LISTED
NASDAQ
Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights
News Preview
Guardant Health (Nasdaq: GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine harnessing artificial intelligence to accelerate drug development, today announced a strategic partnership to deliver novel, scalable, and actionable insights that support biopharmaceutical innovation. This collaboration will combine u...
Themefolio
Profiler
Peergroup
© BusinessWire
26.10.2025
GH
LISTED
NASDAQ
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Frida...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
GH
LISTED
NASDAQ
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across its oncology portfolio will be presented in 15 accepted abstracts at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. These presentations span the cancer care treatment co...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
GH
LISTED
NASDAQ
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the we...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
GH
LISTED
NASDAQ
Alex M. Azar II Joins Guardant Health Board of Directors
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans’ health car...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
GH
LISTED
NASDAQ
Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has reached a strategic agreement with LabFlorida/SunDx Labs to provide residents of senior living communities access to Guardant Shield™, the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for colore...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
GH
LISTED
NASDAQ
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic partnership with PathGroup, one of the nation’s leading partners to physicians, hospitals, and healthcare networks nationwide, to significantly expand the reach of Guardant’s FDA-approved Shield™ blood test. The partnership will bring Shield to mo...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
GH
LISTED
NASDAQ
Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of the latest colorectal cancer (CRC) screening algorithm (V2) for its Shield™ blood test. The study met all primary endpoints and the sensitivity of this new screening algorithm for detecting CRC w...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2025
GH
LISTED
NASDAQ
Guardant Health to Host Investor Day on September 24, 2025
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be hosting an Investor Day on September 24, 2025, in New York City, NY starting at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. The event will feature presentations by several members of the company's leadership team.
Interested parties...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
GH
LISTED
NASDAQ
Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.
Guardant Health’s management is scheduled to participate in a fireside chat on Monday, September 8th at 4:05 p.m. ET. Interested parties ma...
Themefolio
Profiler
Peergroup
© BusinessWire
15.08.2025
GH
LISTED
NASDAQ
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 22, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 239,565 shares of its common stock to 189 new non-executive employees and two non-qualified stock option a...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
GH
LISTED
NASDAQ
Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA.
Guardant Health’s management is scheduled to participate in a fireside chat on Wednesday, August 13th at 9:30 a.m. ET. Interested parties may access...
Themefolio
Profiler
Peergroup
© BusinessWire
30.07.2025
GH
LISTED
NASDAQ
Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights
For the three-month period ended June 30, 2025, as compared to the same period of 2024:
Reported total revenue of $232.1 million, an increase of 31%, driven...
Themefolio
Profiler
Peergroup
© BusinessWire
30.07.2025
GH
LISTED
NASDAQ
Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and health advocate James Van Der Beek to increase awareness about colorectal cancer (CRC) screening and the Shield™ blood test. Approved by the U.S. Food and Drug Administration (FDA) last year, Shield offers a convenient and more...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
GH
LISTED
NASDAQ
New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world. The data, published today in Cancer Re...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
GH
LISTED
NASDAQ
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
GH
LISTED
NASDAQ
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webc...
Themefolio
Profiler
Peergroup
© BusinessWire
10.06.2025
GH
LISTED
NASDAQ
Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world’s most urgent challenges.
Shield is...
Themefolio
Profiler
Peergroup
© BusinessWire
09.06.2025
GH
LISTED
NASDAQ
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company’s minimal residual disease (MRD) blood test, in predicting recurrence in...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
GH
LISTED
NASDAQ
FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
GH
LISTED
NASDAQ
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer (CRC) screening guidelines. The Shield test detects CRC signals in the bloodstream from DNA that is shed by tumors, called circulating tu...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
GH
LISTED
NASDAQ
SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the results of the Phase III SERENA-6 trial - sponsored by AstraZeneca - demonstrate the clinical value of the Guardant360® CDx test in a circulating tumor DNA-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of radiologi...
Themefolio
Profiler
Peergroup
© BusinessWire
31.05.2025
GH
LISTED
NASDAQ
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date evaluating circulating tumor DNA (ctDNA) in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal™ test to stratify the risk of disease recurrence and overall s...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
GH
LISTED
NASDAQ
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360® Liquid test that greatly expand its biomarker identification and cancer subtyping capabilities to help oncologists identify optimal treatment plans. The expanded applications are enabled through the multiomic profiling...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
GH
LISTED
NASDAQ
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from more than 19 studies, including a landmark plenary session on the Phase 3 SERENA-6 trial, demonstrating the critical role of Guardant liquid biopsy tests in cancer screening, therapy selection...
Themefolio
Profiler
Peergroup
© BusinessWire
21.05.2025
GH
LISTED
NASDAQ
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor molecular profiling tests. This new set of tests will help oncologists identify tumor subtypes and match cancer patients to the most effective targeted ther...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
GH
LISTED
NASDAQ
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Guardant Hereditary Cancer test, a germline test that identifies genetic variants associated with cancer risk to help cancer care teams provide optimal patient care.
Germline genetic testing is recommended by medical practice guidelines for...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
GH
LISTED
NASDAQ
Guardant Health to Participate in Upcoming Investor Conferences
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
BofA Securities 2025 Healthcare Conference in Las Vegas, NV
Fireside chat on Wednesday, May 14th at 3:40 p.m. Pacific Time
Jefferies Global Healthcare Conference in New York, NY
Fir...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
GH
LISTED
NASDAQ
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
News Preview
Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company. The list recognizes and honors the top 100 most influential people in global health this year.
“The inclusion on TIME100 Health’s list is more than a personal honor,” said AmirAli...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
GH
LISTED
NASDAQ
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 157,466 shares of its common stock to 139 new non-executive employees and two non-qualified stock option...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
GH
LISTED
NASDAQ
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025.
First Quarter 2025 Financial Highlights
For the three-month period ended March 31, 2025, as compared to the same period of 2024:
Reported total revenue of $203.5 million, an increase of 21%, driven by...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
GH
LISTED
NASDAQ
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its methylation-based Shield™ multi-cancer detection (MCD) test demonstrated high specificity and clinically meaningful sensitivity across ten tumor types,* while also providing information to guide clinical diagnostic evaluatio...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
GH
LISTED
NASDAQ
Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360® Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis—including DNA, RNA, AI-powered PD-L1 and exome-wide methylation data—to provide researchers and cancer care teams with a...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
GH
LISTED
NASDAQ
CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
News Preview
Throughout release, "exome-wide" should read as "genome-wide".
The updated release reads:
GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER
Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
GH
LISTED
NASDAQ
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity™ smart liquid biopsy platform.
Under the multi-year collaboration agreement, Guardant and Pfi...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
GH
LISTED
NASDAQ
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity™ smart liquid biopsy platform at the 2025 American Association for Cancer Resea...
Themefolio
Profiler
Peergroup
© BusinessWire
10.04.2025
GH
LISTED
NASDAQ
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webca...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
GH
LISTED
NASDAQ
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement with Bayshore HealthCare, a leading home and community healthcare service provider in Canada, to offer Guardant’s portfolio of precision oncology tests across the continuum of cancer care through the Bayshore network of clinic...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
GH
LISTED
NASDAQ
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA)...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
GH
LISTED
NASDAQ
Guardant Health Receives ADLT Status From CMS for Shield Blood Test
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for the Shield™ blood test for colorectal cancer (CRC) screening. The U.S. Food and Drug Administration (FDA) approved Shield in July 2024 as...
Themefolio
Profiler
Peergroup
© BusinessWire
28.02.2025
GH
LISTED
NASDAQ
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 110,681 shares of its common stock to 102 new non-executive employees and one non-qualified stock opti...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
GH
LISTED
NASDAQ
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insights” survey, which showed that nine out of ten physicians surveyed are concerned about the percentage of their patients who do not complete colorectal cancer (CRC) screening. In many cases,...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
GH
LISTED
NASDAQ
Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024.
Fourth Quarter 2024 Financial Highlights
For the three-month period ended December 31, 2024, as compared to the same period of 2023:
Total revenue of $201.8 million, an increase of 30...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
GH
LISTED
NASDAQ
Guardant Health to Participate in Upcoming Investor Conferences
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT
Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th...
Themefolio
Profiler
Peergroup
© BusinessWire
07.02.2025
GH
LISTED
NASDAQ
Guardant Health Announces Debt Exchange Transactions
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its outstanding 0% Convertible Senior Notes due 2027 (the “2027 Notes”), pursuant to which the Company will issue $600 milli...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
GH
LISTED
NASDAQ
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
